Skip to contentA
Autolus Therapeutics plc
A
AUTLAutolus Therapeutics plc Q1 2026 · 10-Q
Revenue$26.22M$26.22M+191.9% vs Q1 2025 Net Income-$71.60M-$71.60MN/M vs Q1 2025 EPS Diluted-$0.27-$0.27N/M vs Q1 2025 Operating Income-$59,513,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Autolus Therapeutics plc · CIK 1730463 · Engraved from SEC EDGAR
Free Cash Flowderived-$68,005,000N/M Margins · derivedOperating margin-227.0%+499.3 pt vs Q1 2025
Net margin-273.1%+508.0 pt vs Q1 2025
ended Mar 31, 2026 · filed May 14, 2026 · 44 d after period end